TABLE 4.
Altered cardiac function and disease pathways in embryonic cardiomyocytes after DNMT3a siRNA treatment
| Pathway |
P |
Molecules (n) |
|---|---|---|
| Cardiac function | ||
| Heart rate | 6.73E-29 | 74 |
| Contraction of heart | 6.85E-29 | 58 |
| Hypertrophy of heart | 4.22E-28 | 82 |
| Function of cardiac muscle | 2.57E-22 | 51 |
| Cardiogenesis | 2.55E-17 | 82 |
| Morphology of heart | 2.58E-17 | 74 |
| Arrhythmia | 1.28E-15 | 44 |
| Fibrosis of heart | 5.14E-14 | 40 |
| Abnormal morphology of cardiomyocytes | 3.24E-13 | 25 |
| Organization of sarcomere | 7.17E-13 | 18 |
| Response of heart | 2.37E-09 | 19 |
| Function of cardiomyocytes | 1.51E-07 | 12 |
| Cardiac disease | ||
| Nonischemic cardiomyopathy | 9.48E-20 | 53 |
| Familial heart disease | 1.74E-19 | 29 |
| Dilated cardiomyopathy | 1.87E-18 | 45 |
| Familial cardiomyopathy | 1.76E-17 | 22 |
| Hypertrophic cardiomyopathy | 5.25E-14 | 26 |
| Familial dilated cardiomyopathy | 9.64E-14 | 15 |
| Failure of heart | 8.44E-10 | 41 |
| Coronary disease | 8.51E-10 | 51 |
| Myocardial infarction | 4.22E-08 | 33 |
| Congenital heart disease | 2.53E-06 | 30 |